Daily Newsletter

23 November 2023

Daily Newsletter

23 November 2023

Misericordia Community Hospital launches new emergency unit

The expansion nearly triples the existing facility’s capacity and helps it handle up to 60,000 patient visits annually.

November 22 2023

Misericordia Community Hospital in Edmonton, Canada has unveiled its new emergency department (ED), after an upgrade to the 54-year-old facility.

The new $85m, 5,500m2 facility was delivered as part of a multi-year revamp plan.

It increases the existing emergency department's capacity by nearly three-fold, helping it handle up to 60,000 patient visits annually.

This expansion is expected to alleviate pressure on emergency departments across the region.

The previous department, designed for 25,000 patients, managed 55,000 visits annually.

The new space, with 60 treatment areas as compared to 26 previously, aims to improve efficiency, reduce wait times, and enhance the overall patient experience.

It will comprise specialised care spaces aim to facilitate smooth patient flow, addressing infection control concerns.

Additional upgrades include specialised care spaces, ambulance bays, treatment rooms, radiology facilities, isolation rooms, acute care spaces, and a decontamination suite.

Community donors contributed $2.3m for specialised equipment and staff training.

The Misericordia's overall renovation plan includes future upgrades for the entire hospital, managed by Covenant Health.

Announced in the 2017 budget, construction of this new ED commenced in 2020, as part of the C$400m ($291.81m) over four years for a new hospital in Edmonton.

The construction of this new ED was announced in the 2017 budget and began in 2020.

It is said to be part of the $400m initiative for the development of a new hospital in Edmonton.

Covenant Health CEO Patrick Dumelie was quoted as saying by CBC.ca: “We've had lots of challenges with floods and infrastructure and those sorts of things.

“But the government and AHS have been great in terms of making sure we repair those and keep the old girl going.”

Is it time for the healthcare sector to fully embrace the benefits of digitalization and AI?

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close